These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35397700)

  • 1. A primary rectal neoplasm with novel DDX5-TFEB fusion.
    Zhang M; Yin X; Chen J; Zhu S; Zheng L; Zeng H; Zhou Q; Chen N
    Virchows Arch; 2022 Sep; 481(3):511-516. PubMed ID: 35397700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
    Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
    Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic and Molecular Analysis of the TFEB Fusion Variant Reveals New Members of TFEB Translocation Renal Cell Carcinomas (RCCs): Expanding the Genomic Spectrum.
    Xia QY; Wang XT; Fang R; Wang Z; Zhao M; Chen H; Chen N; Teng XD; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Am J Surg Pathol; 2020 Apr; 44(4):477-489. PubMed ID: 31764220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
    Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
    Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma.
    Caliò A; Brunelli M; Segala D; Pedron S; Tardanico R; Remo A; Gobbo S; Meneghelli E; Doglioni C; Hes O; Zampini C; Argani P; Martignoni G
    Mod Pathol; 2018 Mar; 31(3):474-487. PubMed ID: 29052596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal cell carcinoma with t(6;11)(p21.2;q13)/MALAT1-TFEB fusion: a clinical and pathological analysis].
    Xia Q; Shi S; Shen Q; Wei X; Wang X; Ma H; Lu Z; Zhou X; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):895-9. PubMed ID: 26888508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts.
    Chang IW; Huang HY; Sung MT
    Am J Surg Pathol; 2009 Dec; 33(12):1894-901. PubMed ID: 19809274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEComa-like Neoplasms Characterized by ASPSCR1-TFE3 Fusion: Another Face of TFE3-related Mesenchymal Neoplasia.
    Argani P; Wobker SE; Gross JM; Matoso A; Fletcher CDM; Antonescu CR
    Am J Surg Pathol; 2022 Aug; 46(8):1153-1159. PubMed ID: 35848761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanotic Xp11 translocation renal cancer: report of a case with a unique intratumoral sarcoid-like reaction.
    Ritterhouse LL; Cykowski MD; Hassell LA; Slobodov G; Bane BL
    Diagn Pathol; 2014 Apr; 9():81. PubMed ID: 24735727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcomatoid renal cell tumor harboring a novel BYSL::TFEB fusion with concurrent TFEB amplification.
    Lin R; Flerova E; Wamsley CE; McCue PA; Lallas CD; Jiang W; Huang J; Wang ZX; Li L
    Genes Chromosomes Cancer; 2023 Jun; 62(6):353-360. PubMed ID: 36704911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization.
    Rao Q; Liu B; Cheng L; Zhu Y; Shi QL; Wu B; Jiang SJ; Wang Y; Wang X; Yu B; Zhang RS; Ma HH; Lu ZF; Tu P; Wang JD; Zhou XJ
    Am J Surg Pathol; 2012 Sep; 36(9):1327-38. PubMed ID: 22895266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas.
    Harada S; Caliò A; Janowski KM; Morlote D; Rodriguez Pena MD; Canete-Portillo S; Harbi D; DeFrank G; Magi-Galluzzi C; Netto GJ; Martignoni G; Mackinnon AC
    Mod Pathol; 2021 Nov; 34(11):2055-2063. PubMed ID: 34148064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Tale of 2 Morphologies: Diagnostic Pitfalls in
    Sharma AE; Parilla M; Wanjari P; Segal JP; Antic T
    Int J Surg Pathol; 2021 Feb; 29(1):21-29. PubMed ID: 32886007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features.
    Rao Q; Zhang XM; Tu P; Xia QY; Shen Q; Zhou XJ; Shi QL
    Int J Clin Exp Pathol; 2013; 6(7):1452-7. PubMed ID: 23826432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3.
    Xia QY; Wang XT; Zhan XM; Tan X; Chen H; Liu Y; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Am J Surg Pathol; 2017 May; 41(5):663-676. PubMed ID: 28288037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
    Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
    [No Abstract]   [Full Text] [Related]  

  • 17. TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity.
    Argani P; Reuter VE; Zhang L; Sung YS; Ning Y; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Nov; 40(11):1484-1495. PubMed ID: 27565001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
    Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
    Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerosing TFEB-rearrangement renal cell carcinoma: a recurring histologic pattern.
    Williamson SR; Eble JN; Palanisamy N
    Hum Pathol; 2017 Apr; 62():175-179. PubMed ID: 27864122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
    Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
    Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.